The relationship between the use of metformin and the risk of pancreatic cancer in patients with diabetes: a systematic review and meta-analysis

BMC Gastroenterology

Research

Hong-Dan Fan¹  Qing-Song Mao¹  Jian-Ping Gong¹  Jian Hu² 

[1] Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, 400000, Chongqing, China;Department of Hepatobiliary Surgery, The Second Affiliated Hospital of Chongqing Medical University, 400000, Chongqing, China;Department of Hepatobiliary Surgery, Dianjiang People’s Hospital of Chongqing, 408300, Chongqing, China;

关键词: Metformin;    Pancreatic cancer;    Diabetes mellitus;    Meta-analysis;   

DOI  :  10.1186/s12876-023-02671-0

 received in 2022-12-04, accepted in 2023-02-09,  发布年份 2023

来源: Springer

【 摘 要 】

ObjectiveWe aim to evaluate the relationship between the use of metformin and the risk of pancreatic cancer in type 2 diabetes patients.MethodWe systematically searched the observational studies on PubMed, Embase, Web of Science, Cochrane Library, clinicalrials.gov, and CNKI databases, extracted relevant data, combined the OR value and 95% CI using the random effect model, and conducted a sensitivity analysis, subgroup analysis, and meta-regression to evaluate the size and stability of this relationship.ResultTwenty-nine studies from twenty-four articles met our inclusion criteria, including more than 2 million subjects. Overall analysis showed that compared with no use of metformin, the use of metformin could reduce the risk of pancreatic cancer in patients with type 2 diabetes (OR = 0.82, 95% CI (0.69, 0.98)). Subgroup analysis showed that compared with the use of hypoglycemic drugs, the use of metformin could reduce the risk of pancreatic cancer in patients with type 2 diabetes (OR = 0.79, 95% CI (0.66, 0.94)). However, compared with no drugs or only diet therapy, metformin users might increase the risk of pancreatic cancer (OR = 2.19, 95% CI (1.08, 4.44)). Sensitivity analysis confirmed the stability of the study, and there was no significant publication bias.ConclusionCompared with the no-use of metformin, metformin users with diabetes can reduce the risk of pancreatic cancer. More research is needed to prove it works.

【 授权许可】

CC BY   
© The Author(s) 2023

【 图 表 】

40249_2023_1060_Article_IEq2.gif

Fig. 1

Fig. 8

Fig. 2